Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2007;49:569-576
Published online before print January 29, 2007, doi: 10.1161/01.HYP.0000257914.80918.72
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
49/3/569    most recent
01.HYP.0000257914.80918.72v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Long, C.
Right arrow Articles by Mitchell, B. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Long, C.
Right arrow Articles by Mitchell, B. M.
Related Collections
Right arrow Animal models of human disease
Right arrow Cell signalling/signal transduction
Right arrow Other hypertension
Right arrow Genetically altered mice
Right arrow Hypertension - basic studies
Right arrow Endothelium/vascular type/nitric oxide

(Hypertension. 2007;49:569.)
© 2007 American Heart Association, Inc.


Original Articles

FK506 Binding Protein 12/12.6 Depletion Increases Endothelial Nitric Oxide Synthase Threonine 495 Phosphorylation and Blood Pressure

Cheng Long; Leslie G. Cook; Susan L. Hamilton; Gang-Yi Wu; Brett M. Mitchell

From the Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, Tex.

Correspondence to Brett M. Mitchell, Department of Molecular Physiology and Biophysics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. E-mail brettm{at}bcm.tmc.edu

Chronic treatment with the immunosuppressive drug rapamycin leads to hypertension; however, the mechanisms are unknown. Rapamycin binds FK506 binding protein 12 and its related isoform 12.6 (FKBP12/12.6) and displaces them from intracellular Ca2+ release channels (ryanodine receptors) eliciting a Ca2+ leak from the endoplasmic/sarcoplasmic reticulum. We tested whether this Ca2+ leak promotes conventional protein kinase C–mediated endothelial NO synthase phosphorylation at Thr495, which reduces production of the vasodilator NO. Rapamycin treatment of control mice for 7 days, as well as genetic deletion of FKBP12.6, increased systolic arterial pressure significantly compared with controls. Untreated aortas from FKBP12.6–/– mice and in vitro rapamycin-treated control aortas had similarly decreased endothelium-dependent relaxation responses and NO production and increased endothelial NO synthase Thr495 phosphorylation and protein kinase C activity. Inhibition of either conventional protein kinase C or ryanodine receptor restored endothelial NO synthase Thr495 phosphorylation and endothelial function to control levels. Rapamycin induced a small increase in basal intracellular Ca2+ levels in isolated endothelial cells, and rapamycin or FKBP12.6 gene deletion decreased acetylcholine-induced intracellular Ca2+ release, all of which were reversed by ryanodine. These data demonstrate that displacement of FKBP12/12.6 from ryanodine receptors induces an endothelial intracellular Ca2+ leak and increases conventional protein kinase C–mediated endothelial NO synthase Thr495 phosphorylation leading to decreased NO production and endothelial dysfunction. This molecular mechanism may, in part, explain rapamycin-induced hypertension.


Key Words: endothelium • hypertension • experimental • NO • NO synthase • protein kinases • vasorelaxation




This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
V. L. Watts and E. D. Motley
Role of Protease-Activated Receptor-1 in Endothelial Nitric Oxide Synthase-Thr495 Phosphorylation
Experimental Biology and Medicine, February 1, 2009; 234(2): 132 - 139.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. DeMorrow, H. Francis, E. Gaudio, J. Venter, A. Franchitto, S. Kopriva, P. Onori, R. Mancinelli, G. Frampton, M. Coufal, et al.
The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway
Am J Physiol Gastrointest Liver Physiol, December 1, 2008; 295(6): G1150 - G1158.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Jabs, S. Gobel, P. Wenzel, A. L. Kleschyov, M. Hortmann, M. Oelze, A. Daiber, and T. Munzel
Sirolimus-induced vascular dysfunction increased mitochondrial and nicotinamide adenosine dinucleotide phosphate oxidase-dependent superoxide production and decreased vascular nitric oxide formation.
J. Am. Coll. Cardiol., June 3, 2008; 51(22): 2130 - 2138.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J.-e. Obata, Y. Kitta, H. Takano, Y. Kodama, T. Nakamura, A. Mende, K.-i. Kawabata, Y. Saitoh, D. Fujioka, T. Kobayashi, et al.
Sirolimus-Eluting Stent Implantation Aggravates Endothelial Vasomotor Dysfunction in the Infarct-Related Coronary Artery in Patients With Acute Myocardial Infarction
J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1305 - 1309.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
C. Long, L. G. Cook, G.-Y. Wu, and B. M. Mitchell
Removal of Fkbp12/12.6 From Endothelial Ryanodine Receptors Leads to an Intracellular Calcium Leak and Endothelial Dysfunction
Arterioscler Thromb Vasc Biol, July 1, 2007; 27(7): 1580 - 1586.
[Abstract] [Full Text] [PDF]